- Home
- JAGU vs TVRD Comparison
JAGU vs TVRD Comparison
Compare JAGU & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAGU | TVRD |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 27.5M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | JAGU | TVRD |
|---|---|---|
| Price | $1.03 | $1.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 176.9K | ★ 225.4K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.67 | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.98 | $0.93 |
| 52 Week High | $3.60 | $5.90 |
Technical Indicators
Market Signals| Indicator | JAGU | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 30.64 |
| Support Level | N/A | $0.93 |
| Resistance Level | $1.76 | $2.02 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 4.90 | 7.43 |
Price Performance
Historical ComparisonAbout JAGU Jaguar Uranium Corp. Class A Common Shares
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.